TROKENDI XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROKENDI XR (TROKENDI XR).
Selective inhibitor of neuronal and glial voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive firing. Also blocks L-type calcium channels and enhances GABA-A receptor activity.
| Metabolism | Hepatic metabolism via glucuronidation (UGT1A1, UGT1A3, UGT1A4, UGT2B7, UGT2B15) and CYP3A4 isoenzymes. Excreted primarily in urine as glucuronide conjugates and unchanged drug. Autoinduction of metabolism occurs with chronic use. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70% of the dose; the remainder is eliminated as metabolites in urine and feces. Biliary excretion is minimal. |
| Half-life | 15-20 hours in healthy adults; allows twice-daily dosing. Steady state reached in 5-7 days. |
| Protein binding | Topiramate is 15-41% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.6-0.8 L/kg; indicates extensive distribution into total body water. |
| Bioavailability | Oral bioavailability is approximately 80%. |
| Onset of Action | Oral: Peak plasma concentration at 3-12 hours; clinical effect typically within 24-72 hours. |
| Duration of Action | Approximately 12 hours due to twice-daily dosing; sustained release provides stable plasma levels over 24 hours. |
Initial dose: 50 mg orally twice daily; titrate weekly by 50 mg/day to a target maintenance dose of 200-400 mg/day in two divided doses; maximum 400 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 30-49 mL/min: maximum 200 mg/day; GFR 15-29 mL/min: maximum 150 mg/day; GFR <15 mL/min or hemodialysis: maximum 100 mg/day with supplemental dose of 100 mg after 4-hour hemodialysis. |
| Liver impairment | Child-Pugh Class A: reduce dose by 20%; Class B: reduce by 50%; Class C: avoid use. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at lower end of dosing range due to age-related renal impairment; consider monitoring renal function and titrate slowly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TROKENDI XR (TROKENDI XR).
| Breastfeeding | Topiramate is excreted into human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.7 to 0.9. Infant serum levels can reach up to 10-20% of maternal therapeutic levels. Breastfeeding is not recommended due to potential adverse effects in the infant, including diarrhea, somnolence, and poor feeding. |
| Teratogenic Risk | Trokendi XR (topiramate) is classified as Pregnancy Category D. There is evidence of human fetal risk based on data from pregnancy registries. First trimester exposure increases the risk of oral clefts (cleft lip with or without cleft palate) approximately 3- to 5-fold compared to unexposed infants. Second and third trimester exposure is associated with an increased risk of low birth weight and small for gestational age. Topiramate may also cause metabolic acidosis during pregnancy, which can affect the fetus. |
■ FDA Black Box Warning
Explicit FDA boxed warning: Increased risk of suicidal thoughts or behavior in patients taking antiepileptic drugs; monitor for emergence or worsening of depression, suicidal thoughts/behavior, or unusual changes in mood or behavior.
| Serious Effects |
History of hypersensitivity to topiramate or any component of the formulation; concurrent use with other medications producing metabolic acidosis (e.g., carbonic anhydrase inhibitors) due to additive risk; pregnancy (due to teratogenicity) unless benefit outweighs risk; severe renal impairment (CrCl <30 mL/min) for extended-release formulations.
| Precautions | Suicidal behavior and ideation; aseptic meningitis; hypersensitivity reactions (DRUG-induced hypersensitivity syndrome, Stevens-Johnson syndrome); hepatotoxicity; pancreatitis; blood dyscrasias (agranulocytosis, thrombocytopenia); teratogenicity (fetal anticonvulsant syndrome); worsening of seizures; dizziness and somnolence; hyponatremia. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum topiramate levels throughout pregnancy as clearance may increase. Assess maternal acid-base status with serum bicarbonate levels due to risk of metabolic acidosis. Perform fetal ultrasound to evaluate for oral clefts after first trimester exposure. Monitor fetal growth in the second and third trimesters. Neonates should be monitored for withdrawal symptoms, metabolic acidosis, and low birth weight. |
| Fertility Effects | Topiramate may cause reproductive dysfunction in women, including anovulation, menstrual irregularities, and decreased fertility. It can also decrease serum estradiol levels and alter hormonal contraceptive efficacy. In men, no significant effects on fertility have been reported. |